CMC(603122)2024-10-23 09:43Financial Performance - Revenue for Q3 2024 was ¥230,169,053.57, a decrease of 14.09% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥4,030,001.72, down 69.34% year-on-year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥1,011,333.36, a decline of 89.43% compared to the previous year[2] - Basic earnings per share for Q3 2024 was ¥0.01, a decrease of 66.67% year-on-year[3] - Diluted earnings per share for Q3 2024 was also ¥0.01, reflecting a 66.67% decline compared to the same period last year[3] - Total operating revenue for the first three quarters of 2024 was CNY 710,974,440.58, a decrease of 14.7% compared to CNY 833,171,189.81 in the same period of 2023[17] - Net profit for the first three quarters of 2024 was CNY 27,262,389.89, a decline of 38.0% from CNY 44,059,418.79 in the same period of 2023[17] - The company reported a basic earnings per share of CNY 0.07 for the first three quarters of 2024, compared to CNY 0.11 in the same period of 2023[18] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥2,549,482.37, indicating cash flow challenges[2] - Cash flow from operating activities was CNY 789,703,867.87 for the first three quarters of 2024, a decrease of 15.6% from CNY 935,879,513.79 in the same period of 2023[19] - The net cash flow from operating activities was -2,549,482.37 CNY, an improvement from -53,485,130.65 CNY in the previous year[20] - Total cash inflow from operating activities was 824,285,173.74 CNY, compared to 948,675,860.19 CNY in the same period last year[20] - Cash outflow from operating activities totaled 826,834,656.11 CNY, down from 1,002,160,990.84 CNY year-over-year[20] - The net cash flow from investing activities was -16,543,872.16 CNY, a decline from 5,619,894.87 CNY in the previous year[20] - Cash inflow from financing activities was 410,557,416.75 CNY, compared to 331,220,938.30 CNY in the same period last year[20] - The net cash flow from financing activities was 11,681,304.71 CNY, down from 38,197,346.42 CNY year-over-year[21] - The ending cash and cash equivalents balance was 178,478,283.81 CNY, a decrease from 297,623,457.43 CNY in the previous year[21] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,463,503,262.88, a slight increase of 0.14% from the end of the previous year[3] - Total current liabilities are 291,038,822.52 RMB, up from 285,727,628.78 RMB[14] - Non-current liabilities include long-term borrowings of 540,256.52 RMB, down from 2,183,908.04 RMB[14] - The company’s total liabilities amounted to CNY 293,647,159.10, slightly up from CNY 292,494,548.82 in the previous year[17] - Total assets as of September 30, 2024, are 1,463,503,262.88 RMB, compared to 1,461,406,215.62 RMB at the end of 2023[13] - Short-term borrowings increased significantly to 100,537,252.21 RMB from 53,923,772.38 RMB[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 36,754[8] - The largest shareholder, 合富（香港）控股有限公司, holds 55.00% of shares, totaling 218,937,885 shares[8] Operational Changes - The company reduced non-terminal medical product distribution to improve cash flow, impacting short-term revenue and profit[6] - Research and development expenses increased to CNY 2,710,404.48 in the first three quarters of 2024, compared to CNY 2,463,292.64 in the same period of 2023, reflecting a growth of 10.0%[17] Tax and Other Comprehensive Income - The company recorded a tax expense of CNY 9,766,091.58 for the first three quarters of 2024, down from CNY 19,063,741.02 in the same period of 2023[17] - Other comprehensive income after tax for the first three quarters of 2024 was CNY -2,434,794.93, compared to CNY 3,375,980.83 in the same period of 2023[18]